Ucb S A (UCBJF) 71.4900 $UCBJF Dr. Reddy's (RDY)

New Post Public Reply Private Reply Replies (0) Message Board

Jun 5, 2016 at 1:12 AM

Ucb S A (UCBJF) 71.4900 $UCBJF

Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 39.18 (-0.35), JNJ: 114.76 (+0.27), RDY: 46.97 (-0.10)

UCB (UCBJF) Posts Q1 Results, Reiterates 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:23AM CDT
UCB (UCBJF) reported interim results for the first three months of 2016.
EBS: 43.71 (+0.07), GILD: 86.15 (-0.57), SHPG: 192.14 (+2.10)

UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS
Globe Newswire - Fri Mar 25, 3:01AM CDT
*** Unofficial English translation - For convenience purposes only ***

Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 18.17 (-0.96), BXLT: 46.02 (-0.18), RDY: 46.97 (-0.10)

ZS Pharma Soars on $2.7B Buyout Offer from AstraZeneca
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 11:50AM CST
AstraZeneca (AZN) will acquire biotech company ZS Pharma (ZSPH) for about $2.7 billion, boosting its cardiovascular & metabolic disease portfolio and pipeline.
ZSPH: 89.98 (+0.06), AZN: 29.73 (+0.06)

Aerie (AERI) Posts Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 9:40AM CST
Aerie (AERI) reported third-quarter 2015 loss of 69 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 81 cents.
ADHD: 5.44 (-0.06), AERI: 18.29 (-0.77), SPPI: 7.34 (-0.18)

Dr. Reddy's (RDY) Q2 Earnings Rise Y/Y, Biosimilars in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 10:16AM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 64 cents, up 25.5% from the year-ago quarter.
ANAC: 99.30 (unch), RDY: 46.97 (-0.10), CORT: 5.82 (-0.43)

Valeant (VRX) Loses Over 5% Despite Business Model Review
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 1:22PM CDT
Investigations into Valeant's (VRX) drug pricing policies and accusations related to its business model continue. The company has an uphill battle ahead.
LCI: 24.61 (-0.21), VRX: 28.87 (-0.54), ANAC: 99.30 (unch)

Valeant (VRX) in Focus on Intensifying Government Probe
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:20PM CDT
Valeant (VRX) has hit a rough patch ever since concerns arose about the irrational increase in drug prices by U.S. pharma/biotech companies.
LCI: 24.61 (-0.21), VRX: 28.87 (-0.54), ANAC: 99.30 (unch)

Prothena to Start Phase IIb Study on AL Amyloidosis Drug
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:10PM CDT
Prothena (PRTA) announced that it will commence a phase IIb study on NEOD001 for patients suffering from AL amyloidosis and persistent cardiac dysfunction.
LCI: 24.61 (-0.21), ANAC: 99.30 (unch), PRTA: 48.41 (-1.91)

Shire's Cinryze Gets Fast Track Status for Additional Indication
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:45PM CDT
Shire announced that its HAE drug Cinryze has been granted Fast Track designation for antibody mediated rejection (AMR) in renal transplant recipients by the FDA.
LCI: 24.61 (-0.21), SHPG: 192.14 (+2.10), AZN: 29.73 (+0.06)

UCB Reveals Positive Data on Vimpat Monotherapy Study
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:45PM CDT
UCB (UCBJF) announced encouraging top-line results from a phase III non-inferiority study on Vimpat monotherapy for newly diagnosed partial-onset seizures.
ADHD: 5.44 (-0.06), APRI: 0.44 (unch), ANAC: 99.30 (unch)

Catalyst Starts Congenital Myasthenic Syndromes Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:35PM CDT
Catalyst Pharmaceuticals (CPRX) initiated a pediatric study on Firdapse for congenital myasthenic syndromes in patients aged 2 years to 17 years.
BMRN: 90.00 (-1.52), CPRX: 0.61 (-0.02), APRI: 0.44 (unch)

Lannett (LCI) to Buy UCB's Specialty Generics Subsidiary
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 3:10PM CDT
Lannett Company (LCI) inked a deal with UCB to buy its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc.
LCI: 24.61 (-0.21), JNJ: 114.76 (+0.27), CORT: 5.82 (-0.43)

Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 3:50PM CDT
Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
AMGN: 159.19 (-0.68), LLY: 75.12 (-0.34), NVS: 80.95 (+0.24)

Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 246.96 (-0.16), PGNX: 4.94 (-0.07), RDY: 46.97 (-0.10)

UCB to Expand Cimzia Label Based on Positive Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 1:50PM CDT
UCB S.A. (UCBJF) announced positive results from a phase III study on Cimzia for rheumatoid arthritis in DMARD-naive patients at high risk of disease progression.
VRX: 28.87 (-0.54), BIOD: 0.35 (+0.01)

Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 3:39PM CDT
Immunomedics, Inc. (IMMU) announced that the FDA has granted fast track designation to its lead antibody-drug conjugate program sacituzumab govitecan for the treatment of patients suffering from metastatic non-small cell lung cancer.
VRX: 28.87 (-0.54), IMMU: 4.52 (-0.78), PFE: 34.69 (-0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Therapy Rules Change: Gameday Ups the Ante

Gameday Men's Health: Leading the Safe Peptide Charge Finally, we got some regulatory sanity stepping up to the plate with peptides. You see, the FDA's new interim policy is letting state-licensed compounding pharmacies work their magic with peptides, but only under strict medical watch. And Gameday Men's Health sure ain't wasting any time setting up shop in this fresh...

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Chip Earnings Fuel Market Gains Amid Volatility Dip

Tech Earnings Drive Market Resilience Amid a climate of economic uncertainty, it's refreshing to see semiconductor and tech earnings offering a little backbone to the market. This week, the S&P 500 climbed 1.51%, while the Nasdaq Composite jumped 1.98% over three sessions. It's like watching Rocky get up off the mat—those indices pushing higher when it seemed like they...

Read/Write Labs Tackles Brain-Tech Fusion Ambitions

Buck up, investors! There's a new player on the field marrying AI and neuroscience with some serious firepower and a respectable roster. Read/Write Labs—what you might've known yesterday as Dandelion Science—has kicked off under a fresh banner, amping up efforts to decode and recode our noggin's electrical orchestra. And with the likes of Jim DiCarlo, Dan Yamins, and...

Fannie Mae Q3 2026 Earnings Surpass Expectations

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Aktia Bank: Steady Ratings, Focused Expansion in Europe

Aktia's Ratings Get a Boost In the world of financial minutiae, it was S&P Global Ratings that took the stage, buzzing about Aktia Bank Plc. The bank just had its ratings held steady with an outlook lift from negative to stable. That's like someone throwing you a life jacket when you're treading water; significant if you're trying to stay afloat, not so much if you've got...

ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

VeriSilicon's GLTiny: Game-Changer for Wearable Tech

Revolutionizing Wearable Graphics with GLTiny There's a fresh breeze blowing through the world of wearable tech, and VeriSilicon's GLTiny seems to be at the heart of it. When the silicon giant out of Shanghai tossed GLTiny into the mix, it wasn't just throwing another chip on the barbie. Oh no, this is a real pivot towards juicing up those smart gadgets strapped to your...

Ballard’s HPU Agile-H Poised to Transform Portable Energy

Another Step Forward with Hydrogen Ballard's got another ace up its sleeve with the HPU Agile-H. Now here’s the kicker—everyone’s scrambling for cleaner, more portable energy solutions, and Ballard’s stepped up. Born from their acquisition of GeoPura, this lightweight hydrogen powerhouse is engineered for those spots rudely ignored by the grid. Place your bets on...

Replay Sports Cards Nets STAR Award for Innovation

A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...